Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.brs.2015.06.019 | DOI Listing |
PLoS One
January 2025
Department of Otolaryngology and Head and Neck Surgery, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Objective: This multicenter, randomized, double-blind, placebo-controlled, crossover trial aimed to evaluate whether prolonged noisy galvanic vestibular stimulation improves body balance in patients with vestibulopathy.
Materials And Methods: This trial was registered in the Japan Pharmaceutical Information Center Clinical Trials Information registry (jRCT1080224083). Subjects were 20- to 85-year-old patients who had been unsteady for more than one year and whose symptoms had persisted despite more than six months of rehabilitation.
PLoS One
January 2025
Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.
Background: Cinnamon has been studied as a possible way to control blood glucose and serum cholesterol levels. However, there are no well-conducted randomized controlled trials that can accurately measure the lipid and glucose-lowering effects of Cinnamomum zeylanicum (C. zeylanicum) extract.
View Article and Find Full Text PDFAm J Drug Alcohol Abuse
January 2025
Faillace Department of Psychiatry and Behavioral Sciences, UTHealth McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.
Cocaine use disorder (CUD) is associated with executive functioning impairments linked to serotonergic function. Previous studies reported efficacy with the selective serotonin reuptake inhibitor citalopram in reducing cocaine use. The current study explored moderation and mediation of citalopram effects on cocaine use by performance across executive function domains.
View Article and Find Full Text PDFVaccines (Basel)
January 2025
Leiden University Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Background: Shigella infections remain endemic in places with poor sanitation and are a leading cause of diarrheal mortality globally, as well as a major contributor to gut enteropathy and stunting. There are currently no licensed vaccines for shigellosis but it has been estimated that an effective vaccine could avert 590,000 deaths over a 20-year period. A challenge to effective Shigella vaccine development has been the low immunogenicity and protective efficacy of candidate Shigella vaccines in infants and young children.
View Article and Find Full Text PDFVaccines (Basel)
January 2025
Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China.
: SCTV01E is a tetravalent recombinant COVID-19 vaccine authorized for emergency use in China for adults 18 years and older but not for those under 18. : This Phase 2 trial assessed the safety and immunogenicity of SCTV01E in healthy children and adolescents aged 3 to 17 years, to establish immunobridging with that observed in adults from the efficacy pivotal trial (NCT05308576). : Participants were randomly assigned to receive either 30 µg of SCTV01E or a placebo.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!